Additional file 1 of A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs

Additional file 1: Figure S1. The cohort of Shiba Inu dogs tested in this study (a). Twelve skin swab samples and a faecal sample were collected from each dog in each group, resulted in a total of 12 ´ (10+ 10+ 10 + 20) = 600 skin swab samples and 1 ´ (10+ 10 + 10 + 20) = 50 faecal samples. The twelve skin sites include a buccal sample was collected from three groups; cADpre, cADtreat and Healthy, 1 ´ (10+ 10 + 20) = 40 samples. The twelve skin sites are shown in (b); 1. perilabial area (lips), 2. medial pinnae (concave pinnae), 3. axilla, 4. front paw (dorsal and palmar sides combined), 5. hind paw (dorsal and palmar sides combined), 6. cubital flexor (elbow fold), 7. palmar metacarpal (from carpal to metacarpal pad), 8. flank, 9. inguinal area (groin), 10. abdomen, 11. perineum (from genitalia to anus) and 12. ventral tail (proximal). Age distribution of the participating dogs (c), CADESI-04 (d) and PVAS (e) values for each dog were plotted in the graphs. The values of healthy dogs were given as 0. Asterisks (*) indicate the statistically significant difference; **p < 0.01, ***p < 0.001, ****p < 0.0001 (Kruskal-Wallis test). Ten dogs with untreated cAD dogs (cADpre) received oclacitinib treatment for 2 weeks (cADpost). The treatment efficacy was shown as a statistically significant reduction in CADESI-04 (**p < 0.01, Wilcoxon test; f) and PVAS values (p = 0.0078, Wilcoxon test; g). For these 10 dogs, the CADESI-04 score in 12 different skin sites, the perilabial area, medial pinna, axilla, front paw, hind paw, cubital flexor, palmar metacarpal, flank, inguinal area, abdomen, perineum, and ventral tail, is shown in (h). A significant reduction of CADESI-04 score was observed in inguinal area (*p < 0.05; two-way ANOVA).

附加文件1：图S1。本研究受试的柴犬队列(a)。每组每只犬采集12份皮肤拭子样本与1份粪便样本，最终总计获得12×(10+10+10+20)=600份皮肤拭子样本，以及1×(10+10+10+20)=50份粪便样本。其中，颊部拭子采集自cADpre、cADtreat与健康对照组3组，共计1×(10+10+20)=40份样本。12个皮肤位点如(b)所示：1. 唇周区域（唇部），2. 耳内侧（耳凹面），3. 腋窝，4. 前爪（背侧与掌侧合并采样），5. 后爪（背侧与掌侧合并采样），6. 肘屈区（肘窝），7. 掌骨掌侧区（腕部至掌骨垫区域），8. 胁腹部，9. 腹股沟区（腹股沟），10. 腹部，11. 会阴区（生殖器至肛门区域），12. 尾腹侧（近端段）。受试犬只的年龄分布(c)、每只犬的CADESI-04(d)与PVAS(e)评分均绘制于对应图表中。健康对照组犬只的评分设为0。星号（*）代表统计学显著性差异：**p<0.01，***p<0.001，****p<0.0001（克鲁斯卡尔-沃利斯检验（Kruskal-Wallis test））。10只未接受治疗的cAD患犬（cADpre组）接受奥克拉替尼（oclacitinib）治疗2周，归入cADpost组。治疗效果表现为CADESI-04评分显著降低（**p<0.01，威尔科克森检验（Wilcoxon test）；f图）与PVAS评分降低（p=0.0078，威尔科克森检验（Wilcoxon test）；g图）。针对该10只患犬，12个不同皮肤位点的CADESI-04评分分别为唇周区域、耳内侧、腋窝、前爪、后爪、肘屈区、掌骨掌侧区、胁腹部、腹股沟区、腹部、会阴区与尾腹侧，结果如(h)图所示。其中腹股沟区的CADESI-04评分观察到显著降低（*p<0.05；双向方差分析（two-way ANOVA））。